New hope for kids with rare swelling disorder: early access drug offered

NCT ID NCT07216378

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This program provides early access to an investigational drug called sebetralstat for children aged 2 to 11 with hereditary angioedema (HAE), a condition causing sudden, painful swelling. The drug is taken at the start of an attack to reduce symptoms. It is available to children who have previously been in a sebetralstat study or are new to the drug, if their doctor believes it may help.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hereditary angioedema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • KalVista Investigative Site

    AVAILABLE

    Evansville, Indiana, 47715, United States

  • KalVista Investigative Site

    AVAILABLE

    Wheaton, Maryland, 20902, United States

  • KalVista Investigative Site

    AVAILABLE

    St Louis, Missouri, 63110, United States

  • KalVista Investigative Site

    AVAILABLE

    San Antonio, Texas, 78229, United States